Oncology Medical News about SNDX-275

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

HDAC Inhibitor SNDX-275 Induces Apoptosis in erbB2-Overexpressing Breast Cancer Cells via Down-regulation of erbB3 Expression
Cancer Research, 11/03/09

Huang X et al. – The cellular bias of SNDX–275 is shown to be related partly to the levels of erbB3 expression that directly impact the ability of SNDX–275 to inhibit proliferation/survival of the erbB2–overexpressing breast cancer cells. These findings show that SNDX–275 may be developed as a novel therapeutic agent to treat breast cancers with coexpression of both erbB2 and erbB3.

<< Previous
Identification and prevalence of von Willebrand disease type 2N...

Next >>
Inhibition of the Androgen Receptor as a Novel Mechanism of Taxol...